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Abstract
Background: To date, the majority of studies on hyponatremia focussed on hyponatremia at admission, and came
from developed countries. This study aimed to identify the prevalence of hyponatremia during hospitalization in
patients hospitalized for HF and its association with in-hospital mortality.
Methods: This was an observational study using retrospective data from patients’ records between 2010–2013.
It focused on those patients carrying an ICD-10 code of 150.0(Congestive Heart Failure) as their primary diagnosis.
Hyponatremia during hospitalization was defined as serum sodium level lower than 135 mEq/L obtained from a
blood chemistry measurement on the next days after admission. Patients’ characteristics were examined and the
association between hyponatremia during hospitalization and in-hospital mortality was analyzed.
Results: Among 464 patients hospitalized for HF, hyponatremia during hospitalization was observed in 22 % of
patients with 44 % of this group had normal serum sodium level on admission.
Hyponatremia during hospitalization was associated with lower blood pressure on admission, both systolic and
diastolic, peripheral oedema, ascites and fatigue. Patients having history of hospitalization for cardiac diseases and
renal failure were higher in patients developing hyponatremia during hospitalization. In this group, amiodarone,
heparin, insulin and antibiotics were administered more frequently. Factors potentially increase the risk of
hyponatremia during hospitalization include history of fatigue (OR = 3.23, 95 % CI 1.79–5.82), presence of ascites
(4.14, 1.84–9.31), and administration of heparin (3.85, 1.78–8.31) and antibiotics (3.08, 1.71–5.53). Length of hospital
stay was significantly longer in patients with hyponatremia during hospitalization and in-hospital mortality was also
higher compared to non-hyponatremic patients, 7.7 % and 29.1 %, respectively.
Conclusion: This study found that the prevalence of hyponatremia during hospitalization in patients hospitalized
for HF was almost the same as hyponatremia on admission and administration of heparin and antibiotics can
potentially worsen hyponatremia during hospitalization. In this study population, hyponatremia during
hospitalization was found to be associated with in-hospital mortality.
Background
Hyponatremia is an under-rated problem in managing
patients with heart failure (HF). It shares many patho-
physiologic and prognostic features with HF [1, 2]. Pa-
tients with HF have a high probability of suffering from
hyponatremia, either as a result of disease progression
or the effects of medications [3, 4]. Diuretics cause fluid
loss by excreting sodium, and medications that inhibit the
production or action of aldosterone, (angiotensin convert-
ing enzyme inhibitors, angiotensin receptor blockers,
spironolactone) prevent sodium re-uptake from the kid-
ney. Additionally hyponatremia is a strong independent
predictor of quality of life and mortality in patients with
HF [5–11]. In both hospitalized patients, and those in the
community, the role of sodium depletion as a predictor
of short-term and long-term prognosis, has been docu-
mented [12, 13].
In HF patients, hyponatremia may occur through a
complex process of pathophysiology related to the changes
contributing to HF, including hormonal and neurological
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disorders [3, 14]. Chronic activation of the rennin-
angiotensin-aldosterone system (RAAS) concurrently with
stimulation of the sympathetic nervous system as a
response to inadequate tissue perfusion, stimulates a
counter-productive effect including cardiac remodeling
and water and sodium retention [2, 3]. Arginine-
vasopressin (AVP) is also released as a response to
low cardiac output, to increase intravascular volume.
However, the effect is further counter-productive for
cardiac workload as preload is increased [1, 15, 16].
The risk of hyponatremia among patients with HF is
associated with the severity of the HF [11]. When ven-
tricular dysfunction is severe, the counter-productive
neurohormonal response will also increase, leading to
excessive water reabsorption, after which hyponatremia
can occur [15]. The lower the cardiac output, the greater
the AVP release. Prolonged elevation of this hormone in
the systemic circulation, results in an increase of water
retention leading to a dilution process that may result in
hyponatremia [3, 4].
Most published studies on hyponatremia in patients
with HF have been conducted in developed countries
with advanced resources. Additionally, most studies
focused on the prevalence of hyponatremia on admis-
sion and its association with in-hospital mortality or
long-term prognosis. Studies on hyponatremia from
developing countries with limited resources, and also
studies focusing on hyponatremia during hospitalization
are still lacking. This study aimed to assess the prevalence
of hyponatremia during hospitalization in patients hospi-
talized from HF and its relationship with in-hospital
mortality.
Methods
This was an observational retrospective study conducted
at Fatmawati Hospital, a tertiary teaching hospital, located
in Jakarta Indonesia. A cross-sectional study was de-
signed to assess the prevalence of hyponatremia during
hospitalization and its relationship with in-hospital
mortality. Patients hospitalized for HF between January
2010 and December 2013 aged 18 years or older, coded
with I50.0 according to International classification of
diseases, 10th edition (ICD-10) system and having a
reasonably complete record during hospitalization were
included in this study. Patients diagnosed as having any
malignancy, hepatic cirrhosis, pregnant women and
patients on dialysis, and those with missing records
were excluded from this study. Patient information
collected included demographic profiles, vital signs and
symptoms at admission, past medical history, medica-
tion during hospitalization and blood chemistry pro-
files. All were retrieved manually from medical records.
In this study, a patient was categorized as hyponatre-
mic if serum sodium level was lower than 135 mEq/L
[8, 9]. A patient was categorized as developing hypona-
tremia during hospitalization, if at least one episode of
hyponatremia occurred on the next day after admission
regardless of serum sodium level on admission. Serum
sodium levels were corrected for patients with blood
glucose level >200 mg/dL using correction factor of 2.4
per 100 mg/dL increase of blood glucose level [17].
In–hospital mortality in this study was defined as death
from any cause during hospitalization.
Continuously variable data with normal distribution
are presented as mean ± SD, and Student’s t-test was
used to compare the means of the groups. If the data
was not normally distributed, median with interquar-
tile ranges is quoted and Mann–Whitney U tests were
used to compare groups, respectively. Nominal data
were presented as proportion (percentage) and Chi-
square tests were used to compare the groups. Logistic
regression analysis was performed to identify variables
associated with hyponatremia during hospitalization
by including all variables available at admission and
during hospitalization as independent variables. Logis-
tic regression analysis was also performed to assess the
relationship between hyponatremia, both at admission
and during hospitalization, and in-hospital mortality.
Two tailed p values < 0.05 and odd ratios were consid-
ered to indicate a statistically significant relationship.
All statistical analyses were performed using Statistical
Package for Social Sciences software for Windows ver-
sion 22.0 (SPSS Inc., Chicago, USA).
This study was conducted in accordance with the reg-
ulations on extracting patients’ information from med-
ical records established by Ministry of Health Republic
of Indonesia and has been approved by Fatmawati Hos-
pital Ethics Committee and The Charles Darwin Uni-
versity Ethics Committee.
Results
During 2011–2013, 543 hospitalized patients were coded
with I50.0 for their main diagnosis of hospitalization.
Seventy-nine patients were excluded, due to incomplete
laboratory records, pregnancy or routine hemodialysis.
Compared to other electrolyte disturbances, this study
found that hyponatremia, both on admission and during
hospitalization, was the most prevalent. Table 1 shows
that the prevalence of hyponatremia in patients hospital-
ized for HF is around double that for hypokalemia.
In 464 hospitalized patients with HF included in this
study, hyponatremia was found in 19 % on admission
and 22 % during hospitalization. Distribution of serum
sodium levels is shown in Fig. 1. The mean lowest mea-
sured serum sodium level in patients with hyponatremia
during hospitalization was not significantly different
from the mean lowest serum sodium level of patients
with hyponatremia on admission, 129.8 ± 6.2 mEq/L and
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130 ± 4.2 mmEq/L, respectively, but hyponatremia during
hospitalization comprised more severe serum sodium
depletion (p < 0.001).
As this study focused on hyponatremia during
hospitalization, comparison of patients’ characteristics was
listed between patients with and without hyponatremia
during hospitalization as shown in Table 2. Compared to
those with normonatremia, patients with hyponatremia
during hospitalization were of similar age and gender.
However patients with hyponatremia had lower blood
pressure, both systolic and diastolic, more peripheral
oedema, ascites and fatigue; but chest pain was found to be
less frequent. In term of past medical history, the propor-
tion of patients having a history of hypertension was lower
in patients with hyponatremia but the proportion of
patients having a history of hospitalization for cardiac dis-
eases was higher. Among concomitant diagnoses, renal fail-
ure was found more prevalence in hyponatremic patients.
Other than the xserum sodium and chloride levels, patients
with hyponatremia during hospitalization had significantly
different levels of blood urea nitrogen, lipid profile, albumin
and hepatic enzymes levels (Alanine transaminase– ALT
and Aspartate transaminase- AST) from patients without
hyponatremia. Hyponatremic patients had lower total
cholesterol and high density lipoprotein (HDL) levels.
Serum albumin of patients with hyponatremia during
hospitalization was lower than patients without, and this
might be associated with the higher proportion of patients
having ascites in the hyponatremic group. Elevated hepatic
enzymes level, both AST and ALT, were more prevalent in
patients with hyponatremia during hospitalization.
Table 3 listed medication administered to patients hospital-
ized for HF during hospitalization. While the proportion of
patients receiving diuretics, both furosemide and potassium
sparing diuretics, was not different, the proportion of patients
receiving angiotensin converting enzyme inhibitors (ACEIs)
or angiotensin receptor blockers (ARBs) was lower in pa-
tients with hyponatremia during hospitalisation. The number
of patients receiving amiodarone, heparin, insulin and anti-
biotics was higher in those developing hyponatremia during
hospitalization compared to others without hyponatremia.
Table 4 lists variables associated with hyponatremia
during hospitalization found during multivariable logis-
tic regression analysis. Other than serum sodium level at
admission, other factors associated with hyponatremia
during hospitalization found in this research are history
of fatigue, history of hypertension, presence of ascites at
admission, and administration of heparin and antibiotics
during hospitalization.
Patients developing hyponatremia during hospitalization
showed a significantly longer length of hospital stay
compared to patients without hyponatremia, with median
and interquartile range at 11 (8–15) and 8 (5–12) days,
respectively. In-hospital mortality rate was also observed
higher (p < 0.001) in hyponatremic patients compared to
patients without hyponatremia, at 29.1 % and 7.7 %,
respectively.
In term of in-hospital mortality, as showed in Table 5,
while hyponatremia on admission has no association with
in-hospital mortality, hyponatremia during hospitalization
has an association with odds ratio 3.473 (95 % CI 1.899–
6.351).
Discussion
The present study clearly demonstrates that hyponatremia
is the most prevalent electrolyte disturbance in patients
Table 1 Comparison between sodium and potassium
disturbances observed in patients hospitalized for HF
Type of electrolyte
abnormalities
Prevalence based on time of occurrence
On admission During hospitalization
Hyponatremia 19 % 22 %
Hypernatremia <1 % 1 %
Hypokalemia 10 % 11 %
Hyperkalemia 7 % 4 %
Fig. 1 Distribution of serum sodium level in patients with hyponatremia. on admission and during hospitalisation
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Table 2 Comparisons of patients’ characteristics between patients with normonatremia and patients with hyponatremia during
hospitalization





Age (yrs) 54.2 ± 15.3 52.1 ± 12.9 0.162
Sex (Male) 53.6 % 50.9 % 0.641
Ejection fraction (%) * 39.3 ± 18.4 39.9 ± 20.1 0.846
Ischemia as cause of HF 58.3 % 51.9 % 0.254
Vital signs and symptoms on admission
SBP 129.4 ± 27.4 117.8 ± 24.1 <0.001
DBP 83.1 ± 18.2 76.9 ± 16.8 0.002
Heart rate 94.8 ± 17.6 97.4 ± 18.9 0.212
Respiratory rate 26.7 ± 5.9 27.6 ± 6.1 0.181
Orthopnea 69.6 % 71.6 % 0.703
PND 52.5 % 58.8 % 0.257
Cough 18.8 % 18.6 % 0.971
Chest pain 20.7 % 7.8 % 0.003
Peripheral oedema 61.1 % 72.5 % 0.033
Ascites 8.8 % 21.6 % <0.001
Fatigue 21.5 % 50.9 % <0.001
Medical history
Hypertension 45.1 % 31.4 % 0.014
Diabetes mellitus 22.7 % 24.5 % 0.694
Chronic obstructive pulmonary disease 4.1 % 7.8 % 0.128
Stroke 3.9 % 1.9 % 0.351
Tuberculosis 4.7 % 7.8 % 0.214
Asthma 2.2 % 2.9 % 0.509
Previous hospitalization for cardiac disease 40.9 % 51.9 % 0.046
Concomitant diagnosis
Atrial fibrillation 15.5 % 12.7 % 0.495
Pneumonia 15.7 % 20.6 % 0.248
Renal failure 17.7 % 33.3 % 0.001
Cardiac arrhythmia 4.9 % 5.9 % 0.714
Infectious diseases (other than pneumonia) 4.1 % 5.9 % 0.456
Blood chemistry at admission
Sodium (mEq/L) 139.9 ± 4.5 133.1 ± 6.2 <0.001
Potassium (mEq/L) 4.4 ± 0.4 4.2 ± 0.9 0.824
Chloride (mEq/L) 102. 9 ± 7.4 96.2 ± 8.1 <0.001
Blood glucose (mg/dL) 142.1 ± 73.2 137.1 ± 76.7 0.555
Blood urea nitrogen (mg/dL) 50.7 ± 33.7 73.1 ± 50.9 <0.001
Creatinine (mg/dL) 1.4 ± 1.1 1.7 ± 1.4 0.075
Uric acid (mg/dL) 9.4 ± 5.7 9.0 ± 4.0 0.633
Total cholesterol (mg/dL) 158.0 ± 48.3 137.9 ± 43.1 <0.001
HDL (mg/dL) 35.5 ± 17.9 27.4 ± 12.6 <0.001
Protein total (g/dL) 6.5 ± 0.9 6.3 ± 1.2 0.097
Albumin (g/dL) 3.4 ± 0.6 3.2 ± 0.5 <0.001
Hemoglobin (g/dL) 12.7 ± 2.5 12.8 ± 2.3 0.919
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hospitalized for HF [7, 8, 10]. Based on information on
vital signs and symptoms at admission, this study also
shows that patients with hyponatremia presented with
more severe disease and their prognosis, in term of in-
hospital mortality, was also worse. Compared to patients
without hyponatremia during hospitalization, peripheral
edema and ascites at admission were found to be more
prevalent in patients who developed hyponatremia during
hospitalization. Patients with more severe HF would po-
tentially have these symptoms as a result of poor cardiac
function, i.e. more severe ventricular dysfunction. Left
ventricular ejection fraction (LVEF) has been well known
as an indicator of cardiac pump function, in which lower
LVEF indicates poorer cardiac pump function [12]. In this
study, the average of LVEF is not significantly different be-
tween patients with normonatremia and patients with
hyponatremia during hospitalization, but the average was
calculated from only 47.6 % and 43.4 % of patients with
and without hyponatremia during hospitalization, respect-
ively. In their research, Sato et al. reported signs of a
difference LVEF between these groups but this was not
significant [8].
This study found that a higher proportion of patients
developing hyponatremia during hospitalization had a
history of hospitalization for cardiac diseases but the dis-
ease was not mentioned specifically in medical records.
Previous published studies also reported that more
hyponatremic patients have previous hopstalization for
HF compared to nonhyponatremic patients [8, 13] and
this might be related to the poorer condition of HF in
hyponatremic patients. Renal failure was the only one
Table 2 Comparisons of patients’ characteristics between patients with normonatremia and patients with hyponatremia during
hospitalization (Continued)
Erythrocyte (x1012/L) 4.61 ± 2.16 4.61 ± 1.23 0.996
Hematocrit (%) 39.5 ± 7.0 40.2 ± 6.9 0.544
Leucocyte (x109/L) 8.3 (6.7–10.5) 8.7 (7.0–12.3) 0.187
AST (IU/L) 34 (25–55) 40 (28–83) 0.012
ALT (IU/L) 26 (16–51) 34 (18–88) 0.011








Furosemide 95.3 % 95.1 % 0.931
ACEIs or ARBs 77.3 % 64.7 % 0.01
Sparing diuretics 24.3 % 29.4 % 0.296
Amiodarone 15.5 % 22.5 % 0.093
Potassium
supplement
55.5 % 53.9 % 0.774
Positive
inotropes
9.1 % 31.4 % <0.001
Organic nitrates 62.2 % 54.9 % 0.186
Digoxin 25.1 % 26.5 % 0.785
Aspirin 48.1 % 43.1 % 0.378
Clopidogrel 28.7 % 33.3 % 0.369
Simvastatin 46.4 % 41.2 % 0.348
Heparin 9.1 % 18.6 % 0.007
Warfarin 26.5 % 21.6 % 0.311
CCBs 14.4 % 8.8 % 0.144
Ubiquinone 14.7 % 10.8 % 0.314
Beta blockers 13.5 % 9.8 % 0.318
Laxative agents 40.9 % 38.2 % 0.630
PPIs 14.9 % 22.5 % 0.069
H2RAs 22.1 % 30.4 % 0.083
Allopurinol 18.8 % 20.6 % 0.683
Benzodiazepine 21.8 % 22.5 % 0.876
Insulin 7.5 % 13.7 % 0.049
Oral anti-
diabetics
6.6 % 5.9 % 0.786
Antibiotics 35.4 % 71.6 % <0.001
Beta blockers on
discharge
10.8 % 12.9 % 0.555
Length of
hospital stay
8 (5–12) 11 (8–15) <0.001
In-hospital
death
7.7 % 29.1 % <0.001
Table 4 Factors associated with hyponatremia during
hospitalization
Variable P value Odds ratio 95 % Confidence
interval
History of fatigue <0.001 3.23 1.79–5.83
History of hypertension 0.022 0.49 0.27–0.91
Serum sodium at admission <0.001 0.77 0.73–0.83
Presence of ascites 0.001 4.14 1.85–9.31
Administration of heparin 0.001 3.85 1.78–8.31
Administration of antibiotics <0.001 3.08 1.71–5.53
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concomitant diagnosis found in this study with a significant
correlation between hyponatremic and non-hyponatremic
patients but serum creatinine of both groups was found
not significantly different. However, the average of blood
urea nitrogen in hyponatremic patients was found higher
than non-hyponatremic patients. In acute conditions,
serum creatinine of HF patients may be increased owing to
hypoperfusion and congestion [18] and worsening renal
function in HF patients with congestion has been found as
a predictor for poorer prognosis [19]. Liver function abnor-
mality, detected by AST and ALT, was also found higher in
patients with hyponatremia during hospitalization in this
study. In HF patients, liver function abnormalities indicate
the presence of cardio-hepatic syndrome and, specifically,
higher level of AST and or ALT indicates ischemia within
hepatocytes that should be considered both in managing
the patients and predicting of long-term outcome [20].
In term of medication administered during hospitali
zation, patients with hyponatremia during hospitalization
received less ACEIs or ARBs compared to patients with
normonatremia. In contrast, patients with hyponatremia
received more amiodarone, heparin, insulin and antibi-
otics. This information on medication might also indicate
more severe condition of patients with hyponatremia. The
most used ACEIs or ARBs are administered orally and pa-
tients with severe condition would have difficulty to take
oral medication. In contrast, amiodarone and heparin are
administered parenterally and mostly used in patients with
severe conditions. However, the rate of overall use of
ACEIs or ARBs found in this study at 75 % is higher com-
pared to the rate reported by Callender et al. [21] in their
systematic review on HF in low-middle income countries
and Siswanto et al. [22] in their study on HF in Indonesia,
57 % and 68 %, respectively.
Other than patient’s condition before and at admis-
sion, this study found that medication administered
during hospitalization could also worsen hyponatremia.
While higher serum sodium level at admission and his-
tory of hypertension lowers the risk of hyponatremia
during hospitalization, history of fatigue before admis-
sion and the presence of ascites at admission conversely
increase the risk. Patients received heparin and antibiotics
in this study appeared to have around a three fold higher
risk of developing hyponatremia during hospitalization
with odds ratio 3.85 (95 % CI 1.78-8.31) and 3.08 (1.71-
5.53), respectively. While heparin has been known can
induce hyponatremia [23], administration of antibiotics
might induce hyponatremia by involving a complex asso-
ciation with pathophysiological process of infection.
The overall in-hospital mortality rate found in this
study is 11 % and this is higher than the average of in-
hospital mortality rates reported by Siswanto, et al. in
their report on behalf of The Acute Decompensated Heart
Failure National Registry (ADHERE) research team in
Indonesia at 6.7 % [22].
This is also higher compared to in-hospital mortality
rates of HF patients in developing countries reported
by Callender, et al. [21] and in Asia Pacific reported by
Atherton, et al. [24], 8 % and 4.8 %, respectively. The
higher in-hospital mortality rate found in this study
might be due to more severe conditions of the patients
included in this study. In their report, Siswanto, et al.
found that patients hospitalized for HF in Indonesia
tend to have severe symptoms and lower LVEF [22]. It
is a challenge for primary care providers and general
practitioners in Indonesia to improve management of
HF so that patients with HF will be not delayed to re-
ceive appropriate treatment [25].
While previous studies have revealed the association be-
tween hyponatremia on admission and in-hospital mortal-
ity in patients hospitalized for HF [8, 26, 27], the results of
this study are slightly different. Instead of hyponatremia
on admission, hyponatremia during hospitalization was
found to have an association with in-hospital mortality as
shown in Table 4. In this study, only 56 % of patients de-
veloping hyponatremia during hospitalization were hypo-
natremic on admission and this means that 45 out of 464
patients (9.7 %) included in this study developed hospital-
acquired hyponatremia. In a study with unselected
patients, hospital-acquired hyponatremia was found in
around one third of hospitalized patients and the condi-
tion was associated with increase of length of hospital stay
and in-hospital mortality [28]. Therefore, factors associ-
ated with increased risk of developing hyponatremia dur-
ing hospitalization in patients hospitalized for HF are
important to be studied.
Other than serum sodium levels several other factors
should be considered to assess the hyponatremic status
of a patient hospitalized for HF. Although HF patients
have a high probability of developing hypervolemic
hyponatremia, the possibility of the occurrence of
pseudo-hyponatremia and other types of hyponatremia
need also to be considered in order to administer appro-
priate management. Pseudo-hyponatremia, for instance,
should be considered in HF patients with hyperglycemia
or hypercholesterolemia [29].
As the use of arginine vasopressin receptor antago-
nists, also known as the vaptans, in patients with HF
have been approved, American College Cardiology
Foundation/American Heart Association put these drugs
Table 5 Association between hyponatremia and in-hospital
mortality
Type of hyponatremia
based on time of occurrence
P value Odds ratio 95 % CI
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on their recommendation for managing HF patients devel-
oping hypervolemic hyponatremia [30]. However, role of
the vaptans in reducing all-cause mortality and cardiovas-
cular mortality in patients with HF, including their accept-
ability for long-term use, are still questionable [31–33].
While the vaptans are now might be available in some
developed countries, it is not easy to provide these drugs
in developing countries due to the cost of the medication.
Therefore, the first strategy to minimize hyponatremia-
related problem in patients hospitalized for HF should
be to optimize guideline-driven therapy and to assess
hyponatremia more appropriately [34–37]. Furthermore,
conventional options for managing hyponatremia such as
the use of saline solution, either isotonic or hypertonic,
are still important to be considered [29, 38, 39].
Limitations
This study was conducted in a single tertiary referral hos-
pital, as the number of tertiary hospitals in Indonesia are
more limited compared to secondary hospitals, this study
might not be true representation of the whole population
hospitalized for HF In Indonesia. Hence, further studies
involving more centers and secondary hospitals need to
be conducted to get better picture on hyponatremia in
patients hospitalized for HF in Indonesia.
Patients included in this study were only HF patients
hospitalized with code I50.0 as their main diagnosis in
which the code is only for patients with congestive HF
and patients with right ventricular failure (secondary to
left HF). Therefore, other types of HF were not included
in this study.
Furthermore, hyponatremia in this study was only
assessed by serum sodium level. Hence, patients’ hypo-
natremic status could not be differentiate whether it
was euvolemic, hypervolemic or might be pseudo-
hyponatremia.
As frequently occurrs with retrospective studies, some
important information, such as information on medica-
tion history before hospitalization, could not also be
gathered in this study.
Conclusion
This study confirmed the findings of previous studies
on hyponatremia in patients hospitalized for HF in
which hyponatremia was reported as the most preva-
lent electrolyte disturbances. In addition, this study
found that 56 % of patients having hyponatremia on admis-
sion continue to be hyponatremic during hospitalization.
Factors increasing the risk of hyponatremia during
hospitalization found in this study include history of fa-
tigue, the presence of ascites, and administration of heparin
and antibiotics. In this study population, in-hospital mor-
tality was found to be more associated with hyponatremia
during hospitalization than hyponatremia on admission.
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